ArticleNature2019
MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 588 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
588citing papers in PubMed, 3 pooled it
36.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
588 citing papers in PubMed, 3 syntheses or guidelines pooled it, 845 citations in OpenAlex.
- Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Pooled it
- A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Transformers meets neoantigen detection: a systematic literature review.Journal of integrative bioinformatics · 2024Pooled it
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- CXCL13-expressing CD4Oncoimmunology · 2026Article
- CD39 on CD8European journal of immunology · 2026Review
- Targeting BCL9/BCL9L enhances CD4Acta pharmacologica Sinica · 2026Article
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Single-Cell RNA Sequencing Reveals T-Cell Metabolic Activation and SGPL1 as a Candidate Predictor of PD-1 Resistance in Urothelial Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cell surface ADGRG1 and CD86 expression identifies antitumor CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy.Cancers · 2026Review
- The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice.Nature communications · 2026Article
- Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy.Cell reports. Medicine · 2026Article
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.Science advances · 2026Article
- Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis.bioRxiv : the preprint server for biology · 2026Article
- Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.Cancer immunology research · 2026Article
- CIT tumor lines: A series of immunogenic murine cutaneous squamous cell carcinoma cell lines derived from chemical carcinogenesis.JID innovations : skin science from molecules to population health · 2026Article
528 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors at 4 institutions in 1 country.
Elise AlspachDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Danielle M LussierDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Alexander P MiceliDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Ilya KizhvatovDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Michel DuPageDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Adrienne M LuomaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wei MengDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Cheryl F LichtiDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Ekaterina EsaulovaDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Anthony N VomundDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Daniele RunciDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Jeffrey P WardDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Matthew M GubinDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Ruan F V MedranoDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Cora D ArthurDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
J Michael WhiteDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Kathleen C F SheehanDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Alex ChenDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tyler JacksDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Emil R UnanueDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Maxim N ArtyomovDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Robert D SchreiberDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA. rdschreiber@wustl.edu.
Washington University in St. Louis · USDana-Farber Cancer Institute · USMassachusetts Institute of Technology · USUniversity of California, Berkeley · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Darrell J Irvine · 1985 to 2026
$93.9MPRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MWashington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7MDIABETOGENIC MOLECULE I-AG7--CHEMISTRY AND BIOLOGYR01DK058177 · NIDDK · WASHINGTON UNIVERSITY · PI UNANUE, EMIL RAPHAEL · 2000 to 2020
$7.8MTherapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MDEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPYR01CA190700 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 2015 to 2019
$2.1MAUTOIMMUNE DIABETES: EARLY EVENTS IN ISLETS OF LANGERHANSR01AI114551 · NIAID · WASHINGTON UNIVERSITY · PI UNANUE, EMIL RAPHAEL · 2015 to 2019
$2.1MHoward Hughes Medical InstituteNCI NIH HHS K12 CA167540NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA190700NCI NIH HHS R01 CA238039NCI NIH HHS T32 CA009547NCI NIH HHS T32 CA207021NIAID NIH HHS R01 AI114551NIDDK NIH HHS R01 DK058177NIGMS NIH HHS T32 GM007287
Abstract
The ability of the immune system to eliminate and shape the immunogenicity of tumours defines the process of cancer immunoediting
Indexed as
AnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansImmunotherapyMiceNeoplasms, ExperimentalAntigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class II
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.